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Abstract
Background: Epithelial to mesenchymal transition (EMT) in alveolar epithelial cells (AECs) has been widely
observed in patients suffering interstitial pulmonary fibrosis. In vitro studies have also demonstrated that AECs
could convert into myofibroblasts following exposure to TGF-β1. In this study, we examined whether EMT occurs
in bleomycin (BLM) induced pulmonary fibrosis, and the involvement of bronchial epithelial cells (BECs) in the
EMT. Using an α-smooth muscle actin-Cre transgenic mouse (α-SMA-Cre/R26R) strain, we labelled
myofibroblasts in vivo. We also performed a phenotypic analysis of human BEC lines during TGF-β1 stimulation
in vitro.
Methods: We generated the α-SMA-Cre mouse strain by pronuclear microinjection with a Cre recombinase
cDNA driven by the mouse α-smooth muscle actin (α-SMA) promoter. α-SMA-Cre mice were crossed with the
Cre-dependent LacZ expressing strain R26R to produce the double transgenic strain α-SMA-Cre/R26R. β-
galactosidase (βgal) staining, α-SMA and smooth muscle myosin heavy chains immunostaining were carried out
simultaneously to confirm the specificity of expression of the transgenic reporter within smooth muscle cells
(SMCs) under physiological conditions. BLM-induced peribronchial fibrosis in α-SMA-Cre/R26R mice was
examined by pulmonary βgal staining and α-SMA immunofluorescence staining. To confirm in vivo observations
of BECs undergoing EMT, we stimulated human BEC line 16HBE with TGF-β1 and examined the localization of
the myofibroblast markers α-SMA and F-actin, and the epithelial marker E-cadherin by immunofluorescence.
Results: βgal staining in organs of healthy α-SMA-Cre/R26R mice corresponded with the distribution of SMCs,
as confirmed by α-SMA and SM-MHC immunostaining. BLM-treated mice showed significantly enhanced βgal
staining in subepithelial areas in bronchi, terminal bronchioles and walls of pulmonary vessels. Some AECs in
certain peribronchial areas or even a small subset of BECs were also positively stained, as confirmed by α-SMA
immunostaining. In vitro, addition of TGF-β1 to 16HBE cells could also stimulate the expression of α-SMA and F-
actin, while E-cadherin was decreased, consistent with an EMT.
Conclusion: We observed airway EMT in BLM-induced peribronchial fibrosis mice. BECs, like AECs, have the
capacity to undergo EMT and to contribute to mesenchymal expansion in pulmonary fibrosis.
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Background
Myofibroblast cells, an intermediate cell type between
fibroblasts and smooth muscle cells (SMCs), have been
suggested to play an important role in the development of
interstitial pulmonary fibrosis (IPF), which produces
excessive amounts of extracellular matrix (ECM), leading
to formation of fibroblastic foci [1-3]. However, much is
still unknown regarding the origin of myofibroblasts and
the process resulting in devastating airway aggravation.
Previously, it was suggested that peribronchiolar and
perivascular fibroblasts transdifferentiate into myofibrob-
lasts following exposure to profibrotic mediators such as
TGF-β1 [4]. Alternatively, airway SMCs might dedifferen-
tiate into myofibroblasts, but this possibility has been
ruled out by several studies suggesting that ultrastructural
features and ECM expression profiles of myofibroblasts
are more similar to fibroblasts than to SMCs [1,5].
Recently, fibrocytes originating in the bone marrow have
been proposed to be recruited into the lung after bleomy-
cin (BLM) administration and to act as myofibroblast pro-
genitors [6]. More recently, alveolar epithelial cells (AECs)
have been shown to undergo epithelial to mesenchymal
transition (EMT) to produce myofibroblasts in IPF
patients and following TGF-β1 treatment in vitro [7-9].
Moreover, EMT in AECs has been demonstrated in a
mouse pulmonary fibrosis model [10]. The BLM induced
peribronchial fibrosis mouse model largely recapitulates
histological features of human pulmonary fibrosis [11],
and thus provides a convenient and powerful in vivo tool
that has been the most widely used animal model to study
the pathogenetic mechanisms of pulmonary fibrosis.
However, the common BLM-induced pulmonary fibrotic
model is derived from wild mouse and thus is unsuitable
for tracking the origin of active myofibroblasts in the
development of pulmonary fibrosis, due to their great
"plasticity" and tendency to switch to other phenotypes
[12].
In the present study, we employed the Cre/LoxP recombi-
nase system, using the α-smooth muscle actin (α-SMA)
promoter to drive Cre-dependent recombination in pre-
sumptive myofibroblast cells as well as SMCs. We then
generated an α-SMA-Cre/R26R transgenic mouse strain
that allows permanent β-galactosidase (βgal) labeling in
airway SMCs and the other structural cells undergoing
transdifferentiation into myofibroblasts. Since the recom-
bination is achieved by Cre-dependent removal of the
transcriptional stop sequence between the two LoxP sites
upstream of the lacZ gene in R26R mice, lacZ expression
will permanently label Cre-expressing cells [13,14]. As
expected, our transgenic mouse model accurately labeled
the distribution of SMCs in various organs under physio-
logical conditions; cumulatively recorded the activation
of myofibroblasts in the lung under BLM induced fibrotic
conditions and revealed EMT occurring in AECs and even
in BECs. Moreover, to verify the occurrence of EMT in
BECs in vitro, we treated the human BEC cell line 16HBE
with TGF-β1, which was also capable of inducing EMT.
Methods
Reagents
For histological immunofluorescent staining, anti-α-SMA
monoclonal antibody (mAb) was purchased from Sigma
(reactive with human and mouse α-SMA, Cat A2547);
anti-bovine smooth muscle myosin heavy chains (SM-
MHC) polyclonal antibody (pAb) was kindly provided by
Professor Mary Anne (NIH/NHLBI, US); rabbit anti-
human E-cadherin pAb was purchased from Santa Cruz
Biotechnology (Cat sc-7870), rabbit anti-mouse/human
E-cadherin pAb was purchased from Boster Company
(Cat BA0475). GAPDH mAb was purchased from Chemi-
con (Cat CB1001). Secondary antibodies of goat anti-rab-
bit pAb conjugated with FITC and goat anti-mouse pAb
conjugated with TRITC were purchased from Bethyl(Cat
A120-201F) and Open Biosystems (Cat SAB1428), respec-
tively. Goat anti-mouse pAb conjugated to HRP was pur-
chased from Santa Cruz Biotechnology (Cat sc-2005).
Bleomycin (BLM) used for establishing the peribronchial
fibrosis model was purchased from Nipponkayaku
(Tokyo, Japan). Primers were synthesized in Sangon
(Shanghai, China). All chemicals for βgal staining were
purchased from Jingmei Company (Shenzhen, China).
Generation of the  -SMA-Cre/R26R transgenic mouse 
strain
The Cre recombinase cDNA was PCR amplified from the
pMCI-13Cre plasmid (a gift from Professor F. Costantini,
Department of Genetics, Columbia University, NY, USA)
using the following primers: forward 5'-
GAAGATCTATGCCCAAGAAGAAGAGGAAGGTGTC-
CAATTTACTGAC-3' and reverse 5'-CGGAATTCT-
GAACAAACGACCCAAC-3'. The PCR product was then
sub-cloned into the BamHI-EcoRI site of the VSMP8 plas-
mid (a gift of Professor Art Strauch, Dorothy M. Davis
Heart and Lung Research Institute, Columbus, OH, USA)
which contains the mouse αSMA promoter fragment -
1070~+2582, including the first exon and part of first
intron (GenBank: U63129 and M57409). The α-SMA pro-
moter-Cre fragment was released from the construct using
Sphl and EcoRI for transgenic microinjection (Fig. 1).
Transgenic α-SMA-Cre mice were produced by pronuclear
injection of the recombinant DNA fragment into fertilized
F2 eggs of CBA mice using standard microinjection tech-
niques. Offspring from an α-SMA-Cre-carrying transgenic
founder mouse were selected and crossed to the Cre
dependent conditional reporter strain R26R+/+ (Rosa26,
Soriano P)[15].
 αRespiratory Research 2007, 8:1 http://www.biomedcentral.com/1465-9921/8/1
Page 3 of 11
(page number not for citation purposes)
Generation of the BLM-induced pulmonary fibrosis mouse 
model
5–6 wk old SMA-Cre/R26R mice were endotracheally
injected with 80 μl BLM (3 mg/kg in PBS) or with 80 μl
PBS (n = 4 for each group). These mice were sacrificed 20
days later for western blot analysis, βgal and immunoflu-
orescent staining.
Tissue β-galactosidase (βgal) staining
Organs were dissected from BLM or PBS treated transgenic
mice and subjected to βgal staining. Briefly, organs were
fixed in 0.1 M PBS, pH7.3 containing 0.25% glutaralde-
hyde, 2 mM MgCl2, 5 mM EGTA at 4°C for 1–2 hrs. Left
lung lobes were perfused with 1 ml fixing solution by
endotracheal injection and right lobes were ligated and
removed. Tissues were then incubated in wash buffer (0.1
M PBS, pH7.3 with 2 mM MgCl2, 0.01% deoxycholate,
0.02%NP-40) 3 times for 30 min each, and then in stain-
ing buffer (0.1 M PBS, pH7.3 with 1 mg/ml βgal, 2 mM
MgCl2, 0.01% deoxycholate, 5 mM K3Fe(CN)6, 6 mM
K4Fe(CN)6, 0.02% NP-40) at 37°C overnight. Following
staining, wholemount tissues were observed under XTL-
3400 Zoom Stereo Microscope (CANY, Shanghai, China)
or processed by dehydrating, wax embedding, sectioning
at 8 μm intervals and counterstaining with Carmine
Alum. Microscopic analyses were performed with a Leica
DM LB2 microscope equipped with a digital camera.
Lung histology and immunohistochemistry
After sacrificing α-SMA-Cre/R26R mice, right lung lobes
(upper and middle lobes) were dissected and fixed in for-
malin and processed by conventional histological proce-
dures. After sectioning at 4 μm intervals, sections were
dewaxed, rehydrated, blocked with 10% goat serum for 60
min at room temperature and immunofluorescently
stained with α-SMA, SM-MHC or E-cadherin. Sections
were incubated with anti-α-SMA mAb (1:400), anti-
bovine SM-MHC pAb (1:400) or co-incubated with E-cad-
herin pAb (1:100) overnight at 4°C and subsequently
incubated with goat anti-mouse IgG-TRITC (1:800) pAb
or goat anti-rabbit IgG-FITC (1:400) pAb for 1 hour. DAPI
was used to stain nuclei (500 ng/ml in 95% ethanol) for
Transgene construction and βgal staining of lung lobes Figure 1
Transgene construction and βgal staining of lung lobes. A. Transgene fragment for microinjection. The Cre cDNA and 
a Neo polyadenylylation signal were placed under the control of the mouse α-SMA promoter (-1070 to +2582, including the 
first exon and part of the first intron). B. Comparison of βgal staining in the bronchi of R26R and α-SMA-Cre/R26R mice. Pos-
itive βgal staining (blue color) is observed in the bronchi of α-SMA-Cre/R26R mice (a, 20× magnification), but not in R26R mice 
(b, 20× magnification).
a  b 
 
R26R 
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20 sec, and coverslips were mounted with 80% glycerol.
Slides were examined using a Leica DC 500-fluorescence
microscope equipped with a digital camera.
Alternatively, lung sections were processed for Masson's
trichrome staining to detect collagen and elastin. The
staining was carried out using Masson trichrome staining
Kit (Maxim-Bio, Fuzhou, China) according to the manu-
facturer's instruction.
Western Blot
α-SMA protein levels in lungs were evaluated by western
blot as previously described [16]. After cytoplasmic pro-
tein extraction from the lower lobe of right lung of PBS or
BLM-injected mice, protein was quantified using a BCA
assay kit (Pierce, USA) and 20 μg was used for SDS-PAGE
electrophoresis. Following electrophoretic transfer, mem-
branes were incubated with anti-α-SMA mAb (1:1000) in
TBS/T buffer at 4°C overnight. Membranes were incu-
bated with anti-mouse IgG secondary antibody conju-
gated to HRP (1:1000), followed by exposure to ECL
chemiluminescent substrate (Amersham, UK) and digital
scanning in Image station 2000 (Kodak, US). Following
α-SMA blotting, films were placed in stripping buffer (50
mM DTT, 50 mM Tris. HCI,2%SDS) at 50°C for 30 min-
utes, washed 5 times, reblocked and reprobed with
GAPDH mAb (1:800) and HRP conjugated secondary
antibody. Then the membranes went through chemilumi-
nescence as discribed above to detect GAPDH protein in
the same film. α-SMA protein levels were measured by
densitometry, and expressed relative to GAPDH. Dupli-
cate samples were analyzed for each mouse.
Cell culture and immunofluorescent staining
The human bronchial epithelial cell line 16HBE-14o
(16HBE), a generous gift from Professor S. Holgate
(Southampton University, UK) was routinely maintained
in growth medium consisting of MEM (Life Technologies,
USA) and 10% FCS (Shijiqing Co, China). Cells were
seeded into sterile round coverslips placed inside 12-well
plates. On reaching 70% confluence, medium was
changed to FCS-free MEM, and rhTGF-β1 (R&D company,
US) was added to a subset of wells to a final concentration
of 10 μg/L. 72 hours later, all wells were washed twice
with cold PBS and a subset of wells were fixed with cold
methanol:acetone (1:1) at -20°C for 10 min. Coverslips
were removed from the wells and placed on glass slides,
blocked with 10% goat serum for 60 min. Cells on cover-
slips were incubated with anti α-SMA mAb (1:400) or rab-
bit anti human E-cadherin (1:50) overnight at 4°C and
subsequently incubated with goat anti-mouse IgG-TRITC
(1:800) or goat anti-rabbit IgG-FITC (1:400) for 1 hour.
Another subset of wells were fixed with PFA at RT for 20
min and treated with 0.1% TritonX-100 for 5 min. Cover-
slips were removed from wells, placed on slides, blocked
with 10% goat serum for 30 min and incubated with 100
μl Alex 594 phalloidin (1:500) for 20 min at RT. DAPI was
used to stain nuclei (500 ng/ml in 95% ethanol) for 20
sec, and coverslips were mounted with 80% glycerol.
Slides were examined using a Leica DC 500-fluorescence
microscope equipped with a digital camera.
Results
Generation of α-SMA-Cre/R26R transgenic mice
To permanently label myofibroblasts, we firstly generated
transgenic mice bearing an α-SMA promoter driven Cre.
Ten pseudopregnant mice were implanted oviductally
with fertilized eggs injected with the construct, yielding 19
offspring, 4 of which were identified to carry the ran-
domly integrated transgene. Two founder mice were
selected and used to produce inbred strains. We then
crossed an α-SMA-Cre transgenic strain to reporter strain
R26R+/+ whereby Cre-specific recombination at the
ROSA26 locus allows expression of β-galactosidase in
smooth muscle cells and myofibroblasts.
βgal staining corresponds with distribution of the smooth 
muscles of the α-SMA-Cre R26R strain
βgal staining was performed on offspring of the α-SMA-
Cre/R26R and the R26R mice respectively. Positive βgal
staining was observed in the trachea of the α-SMA-Cre/
R26R strain (Fig. 1b), but not in that of the R26R mouse
(Fig. 1a) under anatomy microscopy, confirming that the
βgal staining resulted from α-SMA-driven Cre-mediated
recombination.
As expected, βgal staining was highly restricted to SMCs in
smooth muscle-rich organs isolated from the α-SMA-Cre/
R26R mice (data not shown). In pulmonary arteries and
veins, βgal staining was consistent with the natural distri-
bution of smooth muscle tissue at these sites (Fig. 2a, b).
In the intrapulmonary bronchus (Fig. 2d, g), the staining
was precisely localized to the muscularis layer of the air-
way, which paralleled the immunofluorescent staining
pattern of α-SMA (Fig. 2e, h) and SM-MHC (Fig. 2f, i).
Neither the terminal bronchioles, which lack SMC (Fig.
2c), nor the bronchial epithelia (Fig. 2a,b,c,d,g) showed
positive βgal staining.
A great enhancement of βgal staining in the lungs of the 
double transgenic mice after Bleomycin treatment
The double transgenic mouse strain described above pro-
vides a simple means to follow expression of α-SMA, and
thus the regulation of myofibroblast development during
pulmonary fibrosis. We next endotracheally adminis-
trated BLM in the transgenic mice for induction of lung
injury and fibrosis. As shown in figure 3A~b, in the whole-
mount lung preparations from BLM-treated α-SMA-Cre/
R26R transgenic mice, βgal staining is easily observed. In
contrast, except for the helium area, the staining is notRespiratory Research 2007, 8:1 http://www.biomedcentral.com/1465-9921/8/1
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observed in preparations from PBS-treated transgenic
mice (Fig. 3A~a).
Histological observations reveal a significantly increased
number of βgal staining- positive cells located at subepi-
thelial areas of bronchioles, terminal bronchioles (Fig.
3A~d,f) and tunica media of pulmonary vessels, particu-
larly pulmonary veins (Fig. 3A~f, h arrowheads) in BLM
treated mice. At these sites, distribution of collagen is vis-
ualized by Masson's trichrome staining, showing
increased collagen deposition around the walls of small
veins and terminal respiratory bronchioles and in certain
parenchymal areas (Fig. 3A~j arrowheads). In contrast,
there is only minimal βgal staining (Fig. 3A~c, e, g) and
Masson trichrome staining (Fig. 3A~i) in the lung of con-
trol mice.
Correspondingly, western blot analysis revealed an over-
all increase in lung α-SMA protein in the BLM treated
transgenic mice, compared with the control mice (Fig. 3B)
βgal and immunofluorescent staining in lung tissues of α-SMA-Cre/R26R mice Figure 2
βgal and immunofluorescent staining in lung tissues of α-SMA-Cre/R26R mice. In βgal stained sections (a, b, c, d, g), 
intrapulmonary veins were homogeneously stained (a, b) and pulmonary arteries were heterogeneously stained (a). In the main 
bronchus of pulmonary hilum, unstained ciliated epithelia were surrounded by a βgal stained muscular layer (a, arrowhead), 
βgal staining was not detected in terminal bronchioles, although small veins were positively stained (c). The thin layer of βgal 
staining was observed in the sub-epithelial areas of small and medium bronchi, respectively (arrowheads in b, d, g). The βgal 
stained areas of bronchus (d, g) paralleled the staining pattern for α-SMA (TRITC-labeled, arrowheads in e, h) and SM-MHC 
(FITC-labeled, arrowheads in f, i) (a-c, 100×, d-i, 400× magnification).
a b c
d e f
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Effects of BLM on lung α-SMA protein levels, ECM deposition and βgal staining Figure 3
Effects of BLM on lung α-SMA protein levels, ECM deposition and βgal staining. Panel A: βgal and Masson's tri-
chrome-staining in sections of lung tissue shows βgal staining to wholemount left lung lobes of the PBS-treated (a) and the 
BLM-treated mice (b) (a, b 10× magnification). In moderate bronchi, thickened bronchial wall with homogeneous βgal stained 
fusiform cells was observed in the BLM-treated lungs (d), and not in the PBS-treated mouse (c), Arrowheads indicate that a few 
cells in alveolar wall were positively stained (d). In pulmonary bronchioles and vessels, BLM treated lung demonstrated 
enhanced βgal expression (f, h), compared with that of PBS treated lung (e, g). βgal stained venous wall was thickened (arrow-
head in f) and the positively stained cells infiltrated outwards (arrowhead in h). In the Masson's trichrome-stained lung sections 
(i, j), extensive collagen staining (Blue color) was seen in BLM treated lung (arrowheads in j), but not in the control with PBS (i). 
(c-j 400× magnification). Panel B: Western blot analysis of protein extracts from lower right lobes of the BLM treated mice (2) 
and control mice (1).
A a
b
c
d
e
f
g
h
i
j
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Detection of EMT in bronchial epithelial cells of the α-
SMA-Cre/R26R mice during BLM-induced pulmonary 
fibrosis
As shown in Fig. 4, we also detected a few βgal positive
cells, with basal or columnar epithelial cell morphology,
existing in epithelia lining the bronchioles (Fig. 4b, c
arrowheads) and air-sacs (Fig. 3A~d arrowheads), in the
BLM-treated transgenic mice. This was not observed in the
control mice (Fig. 3A~c,e; Fig. 4a). Using double immun-
ofluorescent staining, with antibodies against α-SMA and
E-cadherin, we further demonstrated that certain cells
located at bronchiolar epithelium of BLM treated mice
were simultaneously stained with these epithelial and
mesenchymal markers (Fig. 4g,h,i arrowheads), indicat-
ing their undergoing of EMT. No common-staining was
found in control mice (Fig. 4d,e,f). We have also found
similar results from lung tissues after BLM treatment at
day 7, 14, 20 and 28.
In vitro phenotype analysis of 16HBE following exposure 
of TGF-β1
In vitro immunofluorescent staining of 16HBE cells
(human bronchial epithelial cell line) demonstrates that
exposure to TGF-β1 results in an apparent reduction of E-
cadherin staining, an epithelial marker, concomitant with
its redistribution from intercellular junction areas into the
cytoplasm (Fig. 5a, b). In contrast, the mesenchymal
marker F-actin, whose expression was detectable only at
the cellular margin before the exposure, shows an
increased level in the epithelial cells where it is diffusely
distributed throughout the cytoplasm after stimulation
with TGF-β1 (Fig. 5c, d). Meanwhile, positive α-SMA
immunofluorescent staining, which was undetectable
prior exposure to TGF-β1, appeared in the cytoplasm in a
small number of the 16HBE cells (Fig. 5e, f).
Discussion
Using the Cre/Loxp system, we generated a transgenic
mouse strain that expressed lacZ specifically in SMCs and
myofibroblasts containing tissues. The βgal expression
pattern in the α-SMA-Cre/R26R transgenic model closely
resembled the expression of endogenous α-SMA in the
airways, and that in the gastrointestinal channel, vessels
and genitourinary tract under normal physiological con-
ditions. These data suggest that the SMP8 promoter region
of the α-SMA gene, including the first exon and part of the
first intron (-1070 to +2582 of the mouse α-SMA pro-
moter), is sufficient to recapitulate endogenous α-SMA
expression patterns, in concordance with previous studies
[17-19].
Smooth muscle-targeted Cre recombinase mice that have
previously been generated by others for study of diseases,
including SM22-CreER and SMMHC-Cre strains in which
Cre is driven by the promoter of SM22 gene or SM-MHC
gene, respectively. Feil and colleagues have generated the
SM22-CreER transgenic mice to the effect that the expres-
sion of the transgene is confined to smooth muscle cells
for studying vascular and gastrointestinal diseases [20].
However, gene knockout studies suggest that SM22 is not
required for vascular and visceral SMC homeostatic func-
tions in the developing mouse [21], and there are no data
demonstrating that SM22 expression signifies myofibrob-
last activation. With regards to the SMMHC-Cre strain that
has also been used to study vascular development and dis-
eases [22], it has been documented that SM-MHC is sel-
dom expressed in non-SMC cells such as myofibroblasts
[23,24]. In contrast, our α-SMA-Cre/R26R strain appears
to be sensitive to myofibroblast activation after BLM expo-
sure, as Cre-mediated recombination is controlled by the
promoter of the gene encoding α-SMA, a marker of myofi-
broblast transition.
Additionally, for the reason that in vivo recombination in
Cre/Loxp system is irreversible, βgal staining in the lung of
our transgenic strain could reflect past and present myofi-
broblast transition events post BLM treatment. This may
assist discovery of the cellular source of the active myofi-
broblasts in the development of pulmonary fibrosis. In
the chronic progression of fibrosis, multiple cycles of
injury and repair may occur repeatedly with a broad time
period and range of sites. Activation of the α-SMA pro-
moter may be a transient event and limited to a subgroup
of cells at a given time point [25]. So the α-SMA-Cre
mouse strain is likely to be highly relevant for studies of
fibrotic diseases and activation of myofibroblasts, and
trace the source of myofibroblasts.
In the BLM-treated α-SMA-Cre/R26R mice, we observed a
number of βgal staining positive cells emerging in the sub-
epithelial areas of bronchioles and terminal bronchioles
and in the ectoblast of vessels, concomitant with extensive
Masson Trichrome-stained extracellular matrix. In com-
parison, in the PBS-treated α-SMA-Cre/R26R mice, βgal
positive cells were seldom seen, suggesting that not only
can the reporter mice demonstrate the inherent distribu-
tion of pulmonary SMCs under physiologic condition,
but also have the capability to sensitively record the trail
of myofibroblast transition in the lung of the mice follow-
ing pathologic stimulation. We demonstrate herein that
increased βgal expression in the lungs of the BLM-treated
mice is mainly to be due to the appearance of myofibrob-
lasts in the subepithelial areas of bronchiole and terminal
bronchiole. Previous studies had shown that airway BLM
administration does not result in remarkable morpholog-
ical changes in the SMC layer [26].
There have been prior suggestions that EMT occurs in the
lung during fibrogenesis, but these suggestions derive
largely from studies of transformed cells or primary AECsRespiratory Research 2007, 8:1 http://www.biomedcentral.com/1465-9921/8/1
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cultured on plastic, the in vivo significance of which is
unclear [7,9]. It has recently been reported from IPF lung
biopsies that epithelial cells had acquired mesenchymal
features, raising the possibility of EMT during fibrogenesis
[8]. More recently, Kim and colleagues developed a trans-
genic mouse reporter strain in which lung epithelial cells
were genetically altered to permanently express βgal, and
their fates are followed in an established model of pulmo-
nary fibrosis induced by intranasal Adeno-TGF-β1. They
showed that βgal-positive cells expressing mesenchymal
markers accumulated within 3 weeks of in vivo TGF-β1
expression, demonstrating that EMT occurs in vivo in an
animal model [10]. As shown at figure 3, we also observed
the occurrence of EMT in parenchymal alveloar areas fol-
lowing BLM stimulation in our α-SMA-Cre/R26R reporter
mice where a few βgal-positive cells located in alveolar
wall demonstrated that the cells were undergoing EMT.
Alternatively, the βgal-stained epithelial cells may simply
βgal and αSMA positively stained bronchial epithelial cells in the α-SMA-Cre R26R mice treated with BLM Figure 4
βgal and αSMA positively stained bronchial epithelial cells in the α-SMA-Cre R26R mice treated with BLM. βgal 
stained lung sections of α-SMA-Cre/R26R mice without and with BLM treatment (a-c). The section from BLM treated mice 
showed a few βgal stained bronchial epithelial cells (arrowheads in b and c), but not from PBS treated mice (a). Double immun-
ofluorescent staining for α-SMA and E-Cadherin was performed on the sections from PBS (d-f) or BLM (g-i) treated mice. d, g: 
FITC-labeled E-cadherin; e, h: TRITC labeled α-SMA. Positive double immunofluorescent staining (g, h, i) was observed in the 
bronchial epithelial cells lining the bronchioles of the BLM-treated lung where βgal staining was detected as above, but not in 
the control (d, e, f). The images of (d) and (e), or (g) and (h) were merged into (f) and (i). The red fluorescence (h arrowhead) 
indicated the positive α-SMA staining and yellow fluorescent staining (i arrowhead) indicated that the epithelial cells positively 
co-stained with α-SMA and E-Cadherin. (all images are 400× magnification).
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Phenotypic analysis of the human bronchial epithelial cell line (16HBE) following exposure to TGF-β1 Figure 5
Phenotypic analysis of the human bronchial epithelial cell line (16HBE) following exposure to TGF-β1. Immun-
ofluorescent staining for E-cadherin (a, b) showed that exposure to TGF-β1 (b) resulted in an apparent reduction and redistri-
bution of E-cadherin from intercellular junction areas into cytoplasm, compared to control (a). Mesenchymal marker F-actin, 
was faintly stained at the cell margin in the control (c), whereas the staining was substantially enhanced and abundantly located 
throughout cytoplasm after TGF-β1 stimulation (d). Immunofluorescent staining for (-SMA was not detected in the cells under 
basal conditions (e), but was observable in a few cells after TGF-β1 exposure (f).
d
e
a b
c
fRespiratory Research 2007, 8:1 http://www.biomedcentral.com/1465-9921/8/1
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demonstrate transcriptional activation of α-SMA gene in
these cells.
Additionally, βgal was stained positively in a few basal
epithelial cells and columnar epithelial cells lining the
bronchiole during bleomycin-induced lung fibrosis in the
reporter mice. The immunofluorescent co-staining of the
both E-cadherin and α-SMA confirmed further that the
BECs were undergoing EMT. When we focused on the BEC
cell line 16HBE in vitro, we found that exposure to TGF-
β1 led to a remarkable myofibroblast cell-like phenotype,
marked by expression of α-SMA and F-actin and the
reduction of the epithelial-specific junction localization
of E-cadherin. Taken together, these observations suggest
that BECs might also be capable of undergoing EMT and
thereby provide another cellular source for the parenchy-
mal aggregation of myofibroblasts during fibrosis.
As mentioned above, however, the present histological
observations in the reporter mice do not support the
rationale that EMT exerts a critical influence on the pro-
gression of pulmonary fibrosis, because EMT indicated by
βgal staining and α-SMA immunostaining was rarely
detected in BECs and AECs of BLM-treated mice. For the
predominant activation of sub-epithelial myofibroblasts
in the development of BLM-treated lung fibrosis, fibrob-
lasts or other sources of progenitors may play more essen-
tial roles which contribute to the pool of expanded
myofibroblasts after lung injury. To what extent does EMT
contribute to the aggravation of fibrosis, whether similar
EMT in BECs occur in IPF patients are all interesting ques-
tions for future studies.
Additionally, the α-SMA-Cre single transgenic strain bear-
ing the α-SMA driven Cre is sufficiently sensitive to test
the function of a candidate gene in SMCs or myofibrob-
lasts on the development of pulmonary fibrosis. Tissue-
specific gene knockout or knock-in can be accomplished
via crossing the α-SMA-Cre mouse to a strain containing a
loxP site flanked sequence of interest.
Conclusion
In conclusion, we have developed a double transgenic
reporter mouse strain to map the natural distribution of
α-SMA-expressing cells in vivo under basal physiological
condition. Moreover, lung cells that do not express α-SMA
under normal conditions may permanently express βgal
via α-SMA activation in response to pathologic stimula-
tion, thus allowing tracking of the cellular source of
myofibroblasts and to definitively test whether EMT
occurs in vivo.
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